FILTER
LATEST ARTICLES
Aerospace in Québec: The Case for an Industrial Policy
August 02, 2017
A proper aerospace industrial policy is needed to ensure the industry’s future success.
Chile: A Hotbed for Technological Innovation
July 14, 2017
Chile’s mining expertise and the industry’s call for creating efficiencies have coalesced into a perfect storm of innovation.
Vancouver Leads North America’s Exploration Revival
July 14, 2017
In Mexico, Alaska and mainland USA, Vancouver companies are leading the exploration revival.
A New Order: Québec’s Supply Chain Reaches Turning Point
June 28, 2017
Are pressures to integrate causing a fundamental change in the market structure of Québec’s aerospace supply chain?
Quality: A Means for Value Creation
June 19, 2017
Firms must shift focus from Quality for Compliance to Quality as a Culture by keeping the end patient in mind.
Gold Mining in Western Australia
June 06, 2017
A stable gold price and more efficient extraction and processing techniques have led to a renewed interest in Western Australia.
Yukon: A stampede of Gold Hunters
June 06, 2017
All of a sudden majors and juniors alike are snapping up properties in Yukon.
Québec’s Aerospace 4.0: A Solution to Cost Pressures?
June 02, 2017
As cost pressures propagate from OEM’s down the value chain, does Industry 4.0 hold the solutions?
Innovation: The Industry’s Backbone
May 24, 2017
The cost of developing new drugs and cures is enormous. A delicate balance between encouraging innovation and controlling the cost of medicines has to be maintained.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
